A PYMNTS Company

US: More evidence surfaces against pay-for-delay

By  |  July 19, 2013

A study commissioned by the Generic Pharmaceutical Association found that settlement payments from pay-for-delay cases result in positive effects for consumers, according to reports. The GPhA announced the findings of the study, performed by Intercontinental Marketing Services, at a press conference. The findings further back regulatory decisions by the US Federal Trade Commission and, more recently, the US Supreme Court, that backed the possibility that the so-called pay-for-delay agreements, which delay the sale of cheaper generic pharmaceuticals so brand names can remain on shelves, can be anticompetitive. Reports say the GPhA’s study found that consumers saved $25.5 billion between 2005 and 2012 through such settlements for 33 different pharmaceutical drugs.

Full Content: Patent Docs

Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.